SCHEMBL3607141

SCHEMBL3607141

CN1CCN(CCS(=O)(=O)O)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAOX Q6QHF9 1/20 0.42
TDP1 Q9NUW8 2/20 0.39
TP53 P04637 2/20 0.39
KDM4E B2RXH2 1/20 0.39
USP2 O75604 1/20 0.39
CYP3A4 P08684 1/20 0.39
MAPT P10636 1/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
RAD52 P43351 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA9 Q16790 2/20 0.36
CYP1A2 P05177 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
TSHR P16473 2/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2403909 0.91
SCHEMBL789961 0.91 PTGS1 (0.39) KDM4EMAPTALOX15MAPK1ALDH1A1
SCHEMBL14414885 0.91 PTGS1 (0.39) KDM4EMAPTALOX15MAPK1ALDH1A1
SCHEMBL63679 0.91 PTGS1 (0.39) KDM4EMAPTALOX15MAPK1ALDH1A1
Propane SCHEMBL28199390 0.88 PTGS1 (0.35) PAOXTDP1TP53KDM4EUSP2
SCHEMBL9391152 0.88 PTGS1 (0.35) PAOXTDP1TP53KDM4EUSP2
SCHEMBL8343269 0.88 PTGS1 (0.35) PAOXTDP1TP53KDM4EUSP2
SCHEMBL25336178 0.88 PTGS1 (0.38) TDP1TP53KDM4EUSP2CYP3A4
SCHEMBL8463674 0.88 PTGS1 (0.38) TDP1TP53KDM4EUSP2CYP3A4
SCHEMBL9897194 0.88 PTGS1 (0.38) TDP1TP53KDM4EUSP2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2091951-B1 PYRIDO[2,3-B]PYRAZINE AND [1,8]-NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS CEPHALON INC (US) 2018-02-28 EP claimed
CN-101437819-B Pyridopyrazines and derivatives thereof as alk and c-MET inhibitors CEPHALON INC 2013-06-19 CN claimed
EP-2091951-A2 PYRIDO[2,3-B]PYRAZINE AND[1,8]-NAPHTYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS CEPHALON, INC. (US) 2009-08-26 EP claimed
CN-101437819-A Pyridopyrazines and derivatives thereof as ALK and c-MET inhibitors CEPHALON INC (US) 2009-05-20 CN claimed
US-20080032972-A1 Pyridopyrazines and derivatives thereof as alk and c-Met inhibitors CEPHALON, INC. (US) 2008-02-07 US claimed
WO-2007130468-A2 PYRIDO [2, 3-B] PYRAZINE AND [1, 8] -NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS CEPHALON, INC. (US) 2007-11-15 WO claimed
US-7026336-B1 4-pyridinylimidazol-2-ylhydrocarbyl amine, (thio)urea, carbamic acid or sulfonamide derivatives, e.g., (2-(4-(4-Chloro-3-methoxy-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl)-2-methyl-propyl)-carbamic acid tert-butyl ester; Raf kinase inhibitors for the treatment of neurotraumatic diseases SMITHKLINE BEECHAM P.L.C. (GB) 2006-04-11 US claimed
WO-2024020164-A2 GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF FIREFLY BIO, INC. (US) 2024-01-25 WO disclosed
WO-2023109942-A1 COMPOUND-LINKER CONSTRUCTS COMPRISING NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2023-06-22 WO disclosed
EP-2091951-B1 PYRIDO[2,3-B]PYRAZINE AND [1,8]-NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS CEPHALON INC (US) 2018-02-28 EP disclosed
CN-101437819-B Pyridopyrazines and derivatives thereof as alk and c-MET inhibitors CEPHALON INC 2013-06-19 CN disclosed
US-8080561-B2 Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors CEPHALON, INC. (US) 2011-12-20 US disclosed
US-20100048576-A1 PYRIDOPYRAZINES AND DERIVATIVES THEREOF AS ALK AND c-MET INHIBITORS CEPHALON, INC. (US) 2010-02-25 US disclosed
WO-2001038324-A2 IMIDAZOLE DERIVATIVES AND THEIR USE AS RAF KINASE INHIBITORS SMITHKLINE BEECHAM P.L.C. (GB) 2001-05-31 WO disclosed
EP-1033913-A1 ZWITTERIONIC FATTY ACID COMPOUNDS FOR ANTI-INFLAMATION Pugliese, Peter T. (US) 2000-09-13 EP disclosed
EP-1033913-A1 ZWITTERIONIC FATTY ACID COMPOUNDS FOR ANTI-INFLAMATION Pugliese, Peter T. (US) 2000-09-13 EP disclosed
US-6114337-A Zwitteronic-fatty acid compounds having anti-inflammatory properties PUGLIESE PETER T (US) 2000-09-05 US disclosed
US-6114337-A Zwitteronic-fatty acid compounds having anti-inflammatory properties PUGLIESE PETER T (US) 2000-09-05 US disclosed
WO-1999027791-A1 ZWITTERIONIC FATTY ACID COMPOUNDS FOR ANTI-INFLAMATION PUGLIESE PETER T (US) 1999-06-10 WO disclosed
WO-1999027791-A1 ZWITTERIONIC FATTY ACID COMPOUNDS FOR ANTI-INFLAMATION PUGLIESE PETER T (US) 1999-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048576-A1 PYRIDOPYRAZINES AND DERIVATIVES THEREOF AS ALK AND c-MET INHIBITORS ALK, MET, RET PAOX 2423/4885TDP1 2394/4885TP53 464/4885
US-20080032972-A1 Pyridopyrazines and derivatives thereof as alk and c-Met inhibitors ALK, MET, RET PAOX 2423/4885TDP1 2394/4885TP53 464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.